Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam-Reference-Cited by-同舟云学术

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam

Published:2021-08-21 Issue:2 Volume:88 Page:655-668
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Ren Song¹,Vishwanathan Karthick²^ORCID,Cantarini Mireille³,Frewer Paul⁴,Hara Indira⁵,Scarfe Graeme⁶,Burke Wendy⁷,Schalkwijk Stein⁸^ORCID,Li Yan⁹,Han David¹⁰,Goldwater Ronald¹¹

Affiliation:

1. Clinical Pharmacology & Quantitative Pharmacology BioPharmaceuticals R&D, AstraZeneca Gaithersburg Maryland USA

2. Clinical Pharmacology & Quantitative Pharmacology CPSS, R&D, AstraZeneca Boston Massachusetts USA

3. Oncology Late Development Oncology R&D, AstraZeneca Cambridge UK

4. Oncology Biometrics, Oncology R&D, AstraZeneca Cambridge UK

5. Patient Safety, Oncology TA, MedImmune‐AstraZeneca Cambridge UK

6. Drug Metabolism and Pharmacokinetics, Oncology R&D, Research & Early Development, AstraZeneca Cambridge UK

7. Covance Clinical Research Unit Leeds UK

8. Clinical Pharmacology & Quantitative Pharmacology CPSS, R&D, AstraZeneca Cambridge UK

9. Integrated Bioanalysis, Clinical Pharmacology & Quantitative Pharmacology BioPharmaceuticals R&D, AstraZeneca Boston Massachusetts USA

10. Parexel International Glendale California USA

11. Parexel International Baltimore Maryland USA

Funder

AstraZeneca

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14994

Reference19 articles.

1. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

2. High MET copy number and MET overexpression: poor outcome in non‐small cell lung cancer patients;Park S;Histol Histopathol,2012

3. Discovery of (S)‐1‐(1‐(Imidazo[1,2‐a]pyridin‐6‐yl)ethyl)‐6‐(1‐methyl‐1H‐pyrazol‐4‐yl)‐1H‐[1,2,3]triazolo[4,5‐b]pyrazine (volitinib) as a highly potent and selective mesenchymal‐epithelial transition factor (c‐Met) inhibitor in clinical development for treatment of cancer;Jia H;J Med Chem,2014

4. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models

5. Abstract CT305: phase I studies of a selective cMet inhibitor AZD6094 (HMPL504/volitinib) in patients with advanced solid tumors;Hua Y;Cancer Res,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triazole antifungal drug interactions—practical considerations for excellent prescribing;Journal of Antimicrobial Chemotherapy;2024-04-17

2. Savolitinib: A Promising Targeting Agent for Cancer;Cancers;2023-09-25

3. A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers;Clinical Pharmacology in Drug Development;2023-02-19

4. Savolitinib for non-small cell lung cancer;Drugs of Today;2023-01

5. Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time;Pharmaceutics;2022-11-17